Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 9/20 | 0.36 |
| ▸ | AXL | P30530 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.33 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667272 | 0.78 | BCL2 (0.47) | MAPTMAP2K1AXLPARP1HPGD | |
| SCHEMBL665999 | 0.77 | KDM4E (0.49) | MAPTMAP2K1NR4A2AXLHPGD | |
| SCHEMBL1212121 | 0.76 | PIM3 (0.43) | MAPTNR4A2CREBBP | |
| SCHEMBL27830381 | 0.75 | PARP1 (0.34) | MAPTPARP1HPGD | |
| SCHEMBL31363646 | 0.72 | PARP1 (0.39) | MAP2K1NR4A2AXLPARP1CREBBP | |
| SCHEMBL31363101 | 0.70 | NR4A2 (0.41) | MAPTMAP2K1NR4A2AXLHPGD | |
| SCHEMBL25395312 | 0.70 | NR4A2 (0.41) | MAP2K1NR4A2CREBBPMKNK1TTBK1 | |
| SCHEMBL30591117 | 0.70 | NR4A2 (0.41) | MAP2K1NR4A2CREBBPMKNK1TTBK1 | |
| SCHEMBL29696538 | 0.69 | PIM3 (0.44) | NR4A2 | |
| SCHEMBL17802189 | 0.69 | PIM3 (0.44) | NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-2396307-B1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-8637532-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | MAPT 4799/4885MAP2K1 4000/4885NR4A2 388/4885 |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | MAPT 4799/4885MAP2K1 4000/4885NR4A2 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.